Study Details
Testing the Drug Remibrutinib for People with Chronic Spontaneous Urticaria
(IRB#: IRB_00192715)
Chronic spontaneous urticaria is a skin condition of itchy hives and/or swelling. This study will test a drug called Remibrutinib to treat people with this condition. The study wants to see if the drug will help people with the disease and is safe. People in the study will be randomly chosen to be treated with Remibrutinib or Dupilumab (an already approved treatment). This comparison will help the study learn which drug works better. Being in the study requires 8 study visits at the clinic for up to 28 weeks. Medical tests will be done during the study to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 18 years and older
- Diagnosis of Chronic Spontaneous Urticaria that is not controlled with antihistamines
- Willing to complete a daily electronic diary throughout the entire study
- Use specific birth control during study participation
- Able to attend in person visits at the study clinic
Exclusion Criteria
- Prior use of Dupilumab
- Other skin conditions that also have chronic itching
- Pregnant or breastfeeding
Will I be paid for my time?
Yes
IRB#: IRB_00192715
PI: Christopher Hull
Department: DERMATOLOGY
Approval Date: 2025-09-10 06:00:00
Specialties: Dermatology
I am Interested